29,285 Shares in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Purchased by Aristides Capital LLC

Aristides Capital LLC bought a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 29,285 shares of the company’s stock, valued at approximately $193,000.

Other large investors have also recently bought and sold shares of the company. Frazier Life Sciences Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the third quarter valued at approximately $11,307,000. Point72 Asset Management L.P. bought a new position in Lexeo Therapeutics in the third quarter valued at $3,348,000. Geode Capital Management LLC grew its position in Lexeo Therapeutics by 86.5% in the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after purchasing an additional 256,635 shares in the last quarter. Privium Fund Management B.V. acquired a new stake in Lexeo Therapeutics in the 4th quarter valued at $909,000. Finally, Exome Asset Management LLC bought a new stake in Lexeo Therapeutics during the 3rd quarter worth about $797,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

LXEO has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, March 26th. Leerink Partners lowered their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday, March 24th. Chardan Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, March 25th. Finally, Royal Bank of Canada decreased their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $22.80.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO opened at $1.79 on Tuesday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average price is $3.74 and its two-hundred day moving average price is $6.23. The company has a market cap of $59.42 million, a PE ratio of -0.57 and a beta of 1.52. Lexeo Therapeutics, Inc. has a twelve month low of $1.45 and a twelve month high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. On average, analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.